Publications by authors named "L E Bang"
Background: Brain health may be impaired years after hospitalization for critical illness, and similar impairments occur after hospitalization for COVID-19. However, it remains unclear which patients are most likely to experience long-term brain health consequences and whether these adverse events differ between non-COVID critical illness and COVID-19.
Methods: In a prospective observational study, we enrolled patients hospitalized for (1) non-COVID critical illness (pneumonia, myocardial infarction, or ICU-requiring conditions) or for (2) COVID-19, from March 2020 to June 2021.
Spontaneous coronary artery dissection (SCAD) presents a life-threatening condition, prevalent among young women, comprising up to 35% of acute coronary syndrome cases. It involves sudden, trauma-free splitting of coronary artery walls, reducing blood flow and mimicking symptoms of acute myocardial infarction. Despite recent attention, treatment remains debated.
View Article and Find Full Text PDFInterleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Trials
November 2024
Background: Inflammation and neurohormonal activation play a significant role in the adverse outcome seen in acute myocardial infarction (AMI) and the development of cardiogenic shock (CS), which is associated with a mortality rate up to 50%. Treatment with anti-inflammatory drugs such as tocilizumab, an interleukin-6 receptor antagonist, has been shown to reduce troponin release and reduce the myocardial infarct size in AMI patients and it may therefore have cardioprotective properties.
Methods: This is a double-blind, placebo-controlled, single-center randomized clinical trial, including adult AMI patients without CS at hospital arrival, undergoing percutaneous coronary intervention (PCI) within 24 h from symptom onset, and at intermediate to high risk of developing CS (ORBI risk score ≥ 10).
Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
Trials
October 2024
Article Synopsis
- Cardiogenic shock (CS) affects 5-10% of acute myocardial infarction (AMI) patients and has a high 30-day mortality rate, with many patients showing signs of risk upon hospital arrival, highlighting the need for effective prevention strategies.
- The study aims to determine if administering low-dose dobutamine after revascularization can prevent hemodynamic instability in AMI patients at risk for in-hospital CS.
- A clinical trial will involve 100 patients, comparing dobutamine's effects on biomarkers and hemodynamic parameters to a placebo, with outcomes measured over several days to assess cardiac function.